(a)
(b)
(c)
Figure 1: -Infliximab scintigraphy of a sarcoidosis patient (patient 3/F) acquired at 6 h (anterior and posterior views (a)) and at 24 h (anterior and posterior views (b)) showing a moderate and diffuse uptake in the lung parenchyma. [18F]-FDG PET/CT images of the same patient showing a focal/hyleal uptake (coronal and transaxial sections (c)).